North America Mucormycosis Market Report

North America Mucormycosis Market Report, By Species (Rhizopus, Cunnighamella, Rhizomucor, Saksenaea, Lichtheimia, Mucor), Diagnosis Method (Magnetic Resonance Imaging, Computed Tomography, Tissue Biopsy), Drugs (Amphotericin B, Isavuconazole, Posaconazole, Voriconazole, Flucytosine, Fluconazole), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Country- North America Market Share, Trend Analysis & Forecast , 2019 - 2028

Report Code : 10888 | Publish Date : Upcoming | Industry : Healthcare | Geography : North America


Mucormycosis is also called as zygomycosis which is a lethal but rare fungal infection caused due to group of fungus called as mucoromycetes. Additionally, the fungus enters into the skin via wounds like cut, scrape, burn or other types of skin trauma. The fungal infection may affect anyone, but it is common in peoples with weakened immune system and may occur in any part of the body. Furthermore, the cases of mucormycosis is also rising in patient which are getting treatments of COVID-19. The steroid medicines are generally used in the management of disease condition in these patients as they are effective in management but they may weaken the immune system and increase the blood sugar levels, which makes patient more susceptible to mucormycosis.   

Market Dynamics- North America Mucormycosis Market 

The North America mucormycosis market is witnessing tremendous growth during forecast period of 2021 to 2027. The risk factors for the development of mucormycosis comprised of cancers, uncontrolled diabetes, neutropenia and organ transplant. The major factors such as increase in incidences of fungal infections is propelling growth of North America mucormycosis market. The increase in cases of immunological diseases is also boosting growth of North America mucormycosis market. However, side effects of the drugs and presence of misbranded drugs may hinder the growth of North America mucormycosis market. 

COVID-19 Impact on North America Mucormycosis Market

The exclusive COVID-19 impact analysis report by Axiom MRC provides a 3600 analysis of micro and macro-economic factors on the mucormycosis market. In addition, complete analysis of changes on mucormycosis expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on North America economies, international trade, business investments, GDP and marketing strategies of key players present in the market. The COVID-19 has almost affected every market is healthcare industries positively or negatively. The mucormycosis market is primarily driven by the emergence of COVID-19 pandemics. Before the pandemic situation, the fungal infection is rare but COVID-19 is causing high healthcare challenges across the globe. The increasing cases of COVID-19 will significantly increase the number of mucormycosis cases across the globe. 


North America Mucormycosis Market- Segmental Overview

The North America mucormycosis market is bifurcated into species, diagnosis method, drugs, distribution channel and country. 

North America Mucormycosis Market by Species

Fungal species such as rhizopus, cuninghamella, rhizomucor, saksenaea, apophysomyces, lichtheimia, mucor and other are comprised in the North America mucormycosis market. In which rhizopus is also contributing to the growth of North America mucormycosis market. The rhizopus is a genus of common saprophytic fungi on plants and specialized parasites on animals. They are found in wide variety of organic substances, including mature fruits and vegetables, jellies, syrups, leather, bread, peanuts and tobacco. 

North America Mucormycosis Market by Diagnosis Methods

Diagnostic methods such as magnetic resonance imaging, computed tomography, tissue biopsy and others are comprised in the North America mucormycosis market. The magnetic resonance imaging is also contributing to the growth of North America mucormycosis market. The high usage of steroids during management of COVID-19 patients is propelling the growth of North America mucormycosis market. The rising technological advancement is also boosting growth of North America mucormycosis market. 

North America Mucormycosis Market by Drugs

Drugs such as Amphotericin B, isavuconazole, Posaconazole, voriconazole, flucytosine, fluconazole and other drugs are comprised in the North America mucormycosis market. In which Posaconazole is also contributing to the growth of North America mucormycosis market. The rising cases of immune suppressant diseases is propelling growth of North America mucormycosis market. The rising cases of mucormycosis is also boosting growth of North America mucormycosis market. 

North America Mucormycosis Market by Distribution Channel 

Distribution channels such as hospital pharmacies, retail pharmacies and online pharmacies are comprised in the North America mucormycosis market. In which retail pharmacies is also contributing to the growth of North America mucormycosis market. The growing patient population is propelling growth of North America mucormycosis market. The rising use of steroids is also boosting growth of North America mucormycosis market. 

North America Mucormycosis Market by Country

The North America mucormycosis market is studied for key countries such as US, Mexico and Canada. In which United States is anticipated to dominate the market in 2020. The rising cases of COVID-19 is propelling growth of North America mucormycosis market. The rising cases of immune suppressant diseases is also boosting growth of North America mucormycosis market. The growing cases of COVID-19 is propelling growth of North America mucormycosis market. 

Key Players in Mucormycosis Market

The major key players such as Natco Pharmaceuticals, Alembic Pharmaceuticals, Gufic Biosciences, Lyca Pharmaceuticals, Emcure Pharmaceuticals, Bharat Serums And Vaccines, Bdr Pharmaceuticals, Cipla Limited, Lifecare Innovations, Synbiotics Limited, Kamla Lifesciences, Cadila Healthcare Limited and Tlc Pharma Labs among others. 

Key Developments in Mucormycosis Market

June 2021: Celon Laboratories launched an alternative drug, Amphotericin B Emulsion for the treatment of mucormycosis.

May 2021: TLC Pharma, a clinical-stage specialty pharmaceutical company, received approval for the New Drug Application (NDA) for Amphotericin B liposome injection (AmphoTLC), form the Central Drugs Standard Control Organization (CDSCO) of India. The drug can be used in the treatment of fungal infections including mucormycosis infections.

2020: Pfizer Inc. in association with its partner Basilea Pharmaceutica Ltd., launched Cresemba (isavuconazole). The drug is used in mucormycosis and invasive aspergillosis.

September 2019: U.S. FDA granted Fast Track designations for intravenous (IV) and oral formulations for fosmanogepix (APX001) developed, by Amplyx Pharmaceuticals.

The report analyses the mucormycosis market based on species, diagnosis method, drugs, distribution channel and country. Various species of fungi covered in mucormycosis market are rhizopus, cuninghamella, rhizomucor, saksenaea, apophysomyces, lichtheimia, mucor and other. By diagnosis method, the market is segmented into the magnetic resonance imaging, computed tomography, tissue biopsy and other. Based on drugs the market is segmented into Amphotericin B, isavuconazole, Posaconazole, voriconazole, flucytosine, fluconazole and other drugs. Based on distribution channel, the market is segmented into the hospital pharmacies, retail pharmacies and online pharmacies. The report also analyses the impact of COVID-19 on the market and it concludes that the COVID-19 has almost affected every market is healthcare industries positively or negatively. The mucormycosis market is primarily driven by the emergence of COVID-19 pandemics. Before the pandemic situation, the fungal infection is rare but COVID-19 is causing high healthcare challenges across the globe. The increasing cases of COVID-19 will significantly increase the number of mucormycosis cases across the globe. The report also comprised of major key players operating in the market. 

Why to buy this report 

  • The report offers changing market dynamics in the mucormycosis markets industry, presenting historical, current and projected market size in terms of value (USD Million)
  • The research study provides an in-depth analysis of the industry value chain focusing on the peer and parent markets of the mucormycosis market
  • It presents a comprehensive assessment of countries exhibiting promising growth, potential and niche segments and a neutral perspective of the mucormycosis market
  • The report also offers strategic recommendations in key business segments based on the market estimations and competitive landscape, mapping the key common trends of mucormycosis market